Semaglutide for treating moderate to advanced liver fibrosis (without cirrhosis) caused by metabolic dysfunction-associated steatohepatitis [ID6458]

  • In development
  • GID-TA11477
  • Expected publication date: TBC

The appraisal has been delayed following a request from the company.

Documents

Documents created during the development process.

Invitation to participate

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6458

Notes

Referral

Topic selection